Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.52 | N/A | -227.59% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.52 | N/A | -227.59% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about recent performance but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current setbacks.
Natera's earnings report indicates significant challenges, particularly reflected in the EPS miss. Despite this, the stock rose by 2.02%, suggesting some investors may be optimistic about the company's long-term potential. The lack of revenue data and guidance adds uncertainty to future expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Feb 23, 2026